MedPath

Effect of canagliflozin on the disposition index, a marker of pancreatic beta-cell function, in type 2 diabetic patients: a randomized controlled study

Not Applicable
Conditions
Type 2 diabetes mellitus
Registration Number
JPRN-UMIN000030208
Lead Sponsor
Osaka University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

(1) Type 1 diabetes mellitus (2) Need insulin treatment (3) History of hypersensitivity to canagliflozin (4) Heart failure (NYHA class IV) (5) eGFR<45 mL/min/1.73 m2 (6) Severe hepatic dysfunction (7) Pregnancy, nursing or planning to become pregnant during the study (8) Suspected or diagnosed malignant tumors (9) Participating in another interventional study (10) Considered by a study physician to be inappropriate for any other reason

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath